Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3
Status:
Completed
Trial end date:
2019-09-26
Target enrollment:
Participant gender:
Summary
Primary objective:
To demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is
superior to placebo in combination with TCS in treating moderate-to-severe atopic dermatitis
(AD).
Secondary objectives:
To evaluate the efficacy of tralokinumab in combination with TCS on severity and extent of
AD, itch, and health-related quality of life compared with placebo in combination with TCS.
To assess the safety of tralokinumab in combination with TCS when used to treat
moderate-to-severe AD for 32 weeks.